Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus

René Adam, Aimery de Gramont, Joan Figueras, Norihiro Kokudo, Francis Kunstlinger, Evelyne Loyer, Graeme Poston, Philippe Rougier, Laura Rubbia-Brandt, Alberto Sobrero, Catherine Teh, Sabine Tejpar, Eric Van Cutsem, Jean Nicolas Vauthey, Lars Påhlman

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi method was used. CRCLM is defined as liver metastases detected at or before diagnosis of the primary CRC. Early and late metachronous metastases are defined as those detected ≤12. months and >12. months after surgery, respectively. To provide information on potential curability, use of high-quality contrast-enhanced computed tomography (CT) before chemotherapy is recommended. Magnetic resonance imaging is increasingly being used preoperatively to aid detection of subcentimetric metastases, and alongside CT in difficult situations. To evaluate operability, radiology should provide information on: nodule size and number, segmental localization and relationship with major vessels, response after neoadjuvant chemotherapy, non-tumoral liver condition and anticipated remnant liver volume. Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide information on the tumour, margin size and micrometastases. Although the treatment strategy depends on the clinical scenario, the consensus was for chemotherapy before surgery in most cases. When the primary CRC is asymptomatic, liver surgery may be performed first (reverse approach). When CRCLM are unresectable, the goal of preoperative chemotherapy is to downsize tumours to allow resection. Hepatic resection should not be denied to patients with stable disease after optimal chemotherapy, provided an adequate liver remnant with inflow and outflow preservation remains. All patients with synchronous CRCLM should be evaluated by a hepatobiliary multidisciplinary team.

Original languageEnglish
Pages (from-to)729-741
Number of pages13
JournalCancer Treatment Reviews
Volume41
Issue number9
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Drug Therapy
Tomography
Neoplasms
Neoplasm Micrometastasis
Liver Neoplasms
Radiology
Magnetic Resonance Imaging

Keywords

  • Colorectal cancer
  • Multidisciplinary team management
  • Surgery
  • Synchronous colorectal liver metastases
  • Systemic therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Adam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., ... Påhlman, L. (2015). Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treatment Reviews, 41(9), 729-741. https://doi.org/10.1016/j.ctrv.2015.06.006

Managing synchronous liver metastases from colorectal cancer : A multidisciplinary international consensus. / Adam, René; de Gramont, Aimery; Figueras, Joan; Kokudo, Norihiro; Kunstlinger, Francis; Loyer, Evelyne; Poston, Graeme; Rougier, Philippe; Rubbia-Brandt, Laura; Sobrero, Alberto; Teh, Catherine; Tejpar, Sabine; Van Cutsem, Eric; Vauthey, Jean Nicolas; Påhlman, Lars.

In: Cancer Treatment Reviews, Vol. 41, No. 9, 01.11.2015, p. 729-741.

Research output: Contribution to journalArticle

Adam, R, de Gramont, A, Figueras, J, Kokudo, N, Kunstlinger, F, Loyer, E, Poston, G, Rougier, P, Rubbia-Brandt, L, Sobrero, A, Teh, C, Tejpar, S, Van Cutsem, E, Vauthey, JN & Påhlman, L 2015, 'Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus', Cancer Treatment Reviews, vol. 41, no. 9, pp. 729-741. https://doi.org/10.1016/j.ctrv.2015.06.006
Adam, René ; de Gramont, Aimery ; Figueras, Joan ; Kokudo, Norihiro ; Kunstlinger, Francis ; Loyer, Evelyne ; Poston, Graeme ; Rougier, Philippe ; Rubbia-Brandt, Laura ; Sobrero, Alberto ; Teh, Catherine ; Tejpar, Sabine ; Van Cutsem, Eric ; Vauthey, Jean Nicolas ; Påhlman, Lars. / Managing synchronous liver metastases from colorectal cancer : A multidisciplinary international consensus. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 9. pp. 729-741.
@article{65b82db2f3114ff09cfc428159ebc482,
title = "Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus",
abstract = "An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi method was used. CRCLM is defined as liver metastases detected at or before diagnosis of the primary CRC. Early and late metachronous metastases are defined as those detected ≤12. months and >12. months after surgery, respectively. To provide information on potential curability, use of high-quality contrast-enhanced computed tomography (CT) before chemotherapy is recommended. Magnetic resonance imaging is increasingly being used preoperatively to aid detection of subcentimetric metastases, and alongside CT in difficult situations. To evaluate operability, radiology should provide information on: nodule size and number, segmental localization and relationship with major vessels, response after neoadjuvant chemotherapy, non-tumoral liver condition and anticipated remnant liver volume. Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide information on the tumour, margin size and micrometastases. Although the treatment strategy depends on the clinical scenario, the consensus was for chemotherapy before surgery in most cases. When the primary CRC is asymptomatic, liver surgery may be performed first (reverse approach). When CRCLM are unresectable, the goal of preoperative chemotherapy is to downsize tumours to allow resection. Hepatic resection should not be denied to patients with stable disease after optimal chemotherapy, provided an adequate liver remnant with inflow and outflow preservation remains. All patients with synchronous CRCLM should be evaluated by a hepatobiliary multidisciplinary team.",
keywords = "Colorectal cancer, Multidisciplinary team management, Surgery, Synchronous colorectal liver metastases, Systemic therapy",
author = "Ren{\'e} Adam and {de Gramont}, Aimery and Joan Figueras and Norihiro Kokudo and Francis Kunstlinger and Evelyne Loyer and Graeme Poston and Philippe Rougier and Laura Rubbia-Brandt and Alberto Sobrero and Catherine Teh and Sabine Tejpar and {Van Cutsem}, Eric and Vauthey, {Jean Nicolas} and Lars P{\aa}hlman",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2015.06.006",
language = "English",
volume = "41",
pages = "729--741",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Managing synchronous liver metastases from colorectal cancer

T2 - A multidisciplinary international consensus

AU - Adam, René

AU - de Gramont, Aimery

AU - Figueras, Joan

AU - Kokudo, Norihiro

AU - Kunstlinger, Francis

AU - Loyer, Evelyne

AU - Poston, Graeme

AU - Rougier, Philippe

AU - Rubbia-Brandt, Laura

AU - Sobrero, Alberto

AU - Teh, Catherine

AU - Tejpar, Sabine

AU - Van Cutsem, Eric

AU - Vauthey, Jean Nicolas

AU - Påhlman, Lars

PY - 2015/11/1

Y1 - 2015/11/1

N2 - An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi method was used. CRCLM is defined as liver metastases detected at or before diagnosis of the primary CRC. Early and late metachronous metastases are defined as those detected ≤12. months and >12. months after surgery, respectively. To provide information on potential curability, use of high-quality contrast-enhanced computed tomography (CT) before chemotherapy is recommended. Magnetic resonance imaging is increasingly being used preoperatively to aid detection of subcentimetric metastases, and alongside CT in difficult situations. To evaluate operability, radiology should provide information on: nodule size and number, segmental localization and relationship with major vessels, response after neoadjuvant chemotherapy, non-tumoral liver condition and anticipated remnant liver volume. Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide information on the tumour, margin size and micrometastases. Although the treatment strategy depends on the clinical scenario, the consensus was for chemotherapy before surgery in most cases. When the primary CRC is asymptomatic, liver surgery may be performed first (reverse approach). When CRCLM are unresectable, the goal of preoperative chemotherapy is to downsize tumours to allow resection. Hepatic resection should not be denied to patients with stable disease after optimal chemotherapy, provided an adequate liver remnant with inflow and outflow preservation remains. All patients with synchronous CRCLM should be evaluated by a hepatobiliary multidisciplinary team.

AB - An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi method was used. CRCLM is defined as liver metastases detected at or before diagnosis of the primary CRC. Early and late metachronous metastases are defined as those detected ≤12. months and >12. months after surgery, respectively. To provide information on potential curability, use of high-quality contrast-enhanced computed tomography (CT) before chemotherapy is recommended. Magnetic resonance imaging is increasingly being used preoperatively to aid detection of subcentimetric metastases, and alongside CT in difficult situations. To evaluate operability, radiology should provide information on: nodule size and number, segmental localization and relationship with major vessels, response after neoadjuvant chemotherapy, non-tumoral liver condition and anticipated remnant liver volume. Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide information on the tumour, margin size and micrometastases. Although the treatment strategy depends on the clinical scenario, the consensus was for chemotherapy before surgery in most cases. When the primary CRC is asymptomatic, liver surgery may be performed first (reverse approach). When CRCLM are unresectable, the goal of preoperative chemotherapy is to downsize tumours to allow resection. Hepatic resection should not be denied to patients with stable disease after optimal chemotherapy, provided an adequate liver remnant with inflow and outflow preservation remains. All patients with synchronous CRCLM should be evaluated by a hepatobiliary multidisciplinary team.

KW - Colorectal cancer

KW - Multidisciplinary team management

KW - Surgery

KW - Synchronous colorectal liver metastases

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=84944904298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944904298&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.06.006

DO - 10.1016/j.ctrv.2015.06.006

M3 - Article

C2 - 26417845

AN - SCOPUS:84944904298

VL - 41

SP - 729

EP - 741

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 9

ER -